Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 4

Brimonidine in the treatment of glaucoma and ocular hypertension

Authors Louis B Cantor

Published 15 December 2006 Volume 2006:2(4) Pages 337—346

Louis B Cantor
Department of Ophthalmology, Indiana University, Indianapolis, IN, USA
Abstract: Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression and vision loss. The alpha2-adrenergic receptor agonist brimonidine effectively lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle glaucoma and ocular hypertension. A fixed combination of brimonidine and timolol, available in some countries, reduces IOP as effectively as concomitant therapy with brimonidine and timolol and offers the convenience of 2 drugs in a single eyedrop. Brimonidine is safe and well tolerated. Its most common side-effects are conjunctival hyperemia, allergic conjunctivitis, and ocular pruritus. The newest formulation of brimonidine, brimonidine-Purite 0.1%, has a higher pH to improve the ocular bioavailability of brimonidine. This formulation contains the lowest effective concentration of brimonidine and is preserved with Purite® to enhance ocular tolerability. Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% solution preserved with benzalkonium chloride. Recent results from preclinical and clinical studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP. The potential for neuroprotection with brimonidine is an added benefit of its use in glaucoma and ocular hypertension.
Keywords: brimonidine, preservative, glaucoma, intraocular pressure, neuroprotection

Download Article [PDF] 

Readers of this article also read:

Towards a new standard of perioperative fluid management

Conor J Shields

Therapeutics and Clinical Risk Management 2008, 4:569-571

Published Date: 11 April 2008

Palonosetron as an anti-emetic and anti-nausea agent in oncology

Matti S Aapro

Therapeutics and Clinical Risk Management 2007, 3:1009-1020

Published Date: 15 January 2008

Vaccination against hepatitis A in children: A review of the evidence

Paolo Bonanni, Sara Boccalini, Angela Bechini

Therapeutics and Clinical Risk Management 2007, 3:1071-1076

Published Date: 15 January 2008

Treatment of non-alcoholic fatty liver disease

Keith G Tolman, Anthony S Dalpiaz

Therapeutics and Clinical Risk Management 2007, 3:1153-1163

Published Date: 15 January 2008

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma

Gennaro D’Amato, Antonello Salzillo. Amedeo Piccolo, Maria D’Amato, Gennaro Liccardi

Therapeutics and Clinical Risk Management 2007, 3:613-619

Published Date: 15 September 2007

Progress in the development of a cervical cancer vaccine

Ursula Winters, Richard Roden, Henry Kitchener, Peter Stern

Therapeutics and Clinical Risk Management 2006, 2:259-269

Published Date: 15 September 2006

Absence of the toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399Ile in Singaporean Chinese

Xiao Hui Liang, Wai Cheung, Chew Kiat Heng, De-Yun Wang

Therapeutics and Clinical Risk Management 2005, 1:243-246

Published Date: 15 October 2005